^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

FOR46

i
Other names: FOR46, FG-3246, FOR 46
Associations
Company:
FibroGen, Fortis Therap
Drug class:
Microtubule inhibitor, CD46-targeted antibody-drug conjugate
Related drugs:
Associations
3ms
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P1, N=56, Completed, Fortis Therapeutics, Inc. | Active, not recruiting --> Completed
Trial completion
|
CD46 (CD46 Molecule)
|
FOR46
over3years
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
Trial completion date: Jun 2020 --> Dec 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
Clinical • Trial completion date • Trial primary completion date
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
FOR46